Humankind Investments LLC Decreases Stake in Boston Scientific Co. (NYSE:BSX)

Humankind Investments LLC decreased its holdings in Boston Scientific Co. (NYSE:BSX) by 4.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,676 shares of the medical equipment provider’s stock after selling 654 shares during the quarter. Humankind Investments LLC’s holdings in Boston Scientific were worth $1,132,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. TFC Financial Management Inc. lifted its stake in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 210 shares during the period. Colonial Trust Co SC lifted its position in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 260 shares during the period. West Oak Capital LLC purchased a new stake in shares of Boston Scientific during the 4th quarter worth approximately $29,000. Valley National Advisers Inc. grew its holdings in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 286 shares during the period. Finally, Fairway Wealth LLC purchased a new position in Boston Scientific in the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity

In other news, EVP John Bradley Sorenson sold 1,201 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the transaction, the executive vice president now owns 25,443 shares of the company’s stock, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares of the company’s stock, valued at approximately $3,441,592.37. This represents a 11.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 300,497 shares of company stock valued at $31,056,815 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $102.87 on Friday. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a 50 day moving average price of $98.68 and a 200 day moving average price of $95.99. The company has a market cap of $152.19 billion, a price-to-earnings ratio of 82.30, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company had revenue of $4.66 billion during the quarter, compared to analysts’ expectations of $4.57 billion. During the same period in the previous year, the company earned $0.56 EPS. The business’s quarterly revenue was up 20.9% compared to the same quarter last year. Sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of research analyst reports. Morgan Stanley boosted their target price on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Evercore ISI boosted their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an “outperform” rating in a research report on Thursday, April 24th. Stifel Nicolaus raised their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Wells Fargo & Company upped their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Finally, UBS Group increased their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Twenty-three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and an average price target of $114.52.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.